Skip to content
DataLookout
Menu

NCT07938099

Real-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary Prevention

StatusActive, Not Recruiting
PhaseNot specified
SponsorXin Li
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria changed
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Major adverse cardiovascular events (MACE)
Timeframe: Patients were followed up from the index date until death, loss to follow-up, or August 31, 2026, whichever occurred first.
All-cause mortality
Timeframe: Patients were followed up from the index date until death, loss to follow-up, or August 31, 2026, whichever occurred first.

Arms and interventions

PCSK9 monoclonal antibody plus statins

PCSK9 monoclonal antibodies include evolocumab, alirocumab, t

Cholesterol absorption inhibitors combined with statins

Cholesterol absorption inhibitors included ezetimibe and hyzetimibe, and statins included lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, and pitavastatin. Exposure was identified through medical insurance reimbursement claims.

Sites

1 site in 1 country

  • Nanjing medical universityNanjing, Jiangsu, China